必须声明标量变量 "@Script_ID"。 舒肝解郁胶囊与舍曲林在抑郁症患者认知功能中的临床价值-《赣南医学院学报》

[1]孙伟力,孙丽新,王亚丽.舒肝解郁胶囊与舍曲林在抑郁症患者认知功能中的临床价值[J].赣南医学院学报,2019,39(12):1226-1230.[doi:10.3969/j.issn.1001-5779.2019.12.010]
 SUN Wei-li,SUN Li-xin,WANG Ya-li.Clinical Value of Shugan Jieyu Capsule and Sertraline in Cognitive Function of Depressive Patients[J].,2019,39(12):1226-1230.[doi:10.3969/j.issn.1001-5779.2019.12.010]
点击复制

舒肝解郁胶囊与舍曲林在抑郁症患者认知功能中的临床价值()
分享到:

《赣南医学院学报》[ISSN:1001-5779/CN:36-1154/R]

卷:
39
期数:
2019年12期
页码:
1226-1230
栏目:
临床研究
出版日期:
2019-12-31

文章信息/Info

Title:
Clinical Value of Shugan Jieyu Capsule and Sertraline in Cognitive Function of Depressive Patients
文章编号:
1001-5779(2019)12-1226-05
作者:
孙伟力1孙丽新2王亚丽3
新乡医学院第二附属医院1.医保门诊; 2.临床心理科; 3.精神三科,河南 新乡 453002
Author(s):
SUN Wei-li1 SUN Li-xin2 WANG Ya-li3
The Second Affiliated Hospital of Xinxiang Medical College 1.Medical Insurance Clinic; 2.Clinical Psychology Department; 3.Psychiatry Department, Xinxiang, Henan 453002
关键词:
抑郁症 舒肝解郁胶囊 舍曲林 认知功能
Keywords:
Depression Shugan Jieyu Capsule Sertraline Cognitive Function
分类号:
R749.4
DOI:
10.3969/j.issn.1001-5779.2019.12.010
文献标志码:
A
摘要:
目的:观察舒肝解郁胶囊与舍曲林片治疗抑郁症的疗效、不良反应,并寻找抑郁症患者治疗前后认知功能的临床价值。方法:将2016年1月至12月于河南省精神卫生中心门诊或病房接受治疗的轻、中度抑郁症患者96例随机分为2组:舒肝解郁组和舍曲林组(共同称为“患者组”),另设健康对照组40例。应用韦氏智力测验(WAIS-RC)评估患者组在治疗前及治疗后第6周末的认知功能,采用副反应量表(TESS)观察患者组治疗后2周、4周和6周药物治疗的不良反应。结果:在认知功能方面,治疗前,3组在领悟、算术、数字广度、词汇、数字符号总数和正确数、填图分测验存在显著差异(P<0.05); 治疗后,舒肝解郁组在领悟、算术、词汇和数字符号分测验中的成绩高于治疗前,而相似性分测验的成绩低于治疗前,差异显著(t=-3.218,P=0.002; t=-2.314,P=0.038; t-=-2.974,P=0.005; t=-3.151,P=0.037)。舍曲林组在治疗后,其数字广度分、词汇分、数字符号分测验的成绩均优于治疗前,差异有统计学意义(t=-3.241,P=0.013; t=-3.241,P=0.013; t=-3.112,P=0.001)。 结论:(1)舒肝解郁胶囊是一种既有效又安全的抗抑郁药。(2)抑郁症患者存在明显的认知功能障碍,舒肝解郁胶囊、舍曲林片治疗后认知功能有改善。
Abstract:
Objective: To observe the efficacy and adverse reactions of Shugan Jieyu Capsule and Sertraline Tablets in the treatment of depression, and to find out the clinical value of cognitive function in patients with depression before and after treatment. Methods: From January to December 2016, 96 patients with mild or moderate depression who were treated in the outpatient or ward of Henan Mental Health Center were randomly divided into two groups: Shugan Jieyu group and Sertraline group(collectively referred to as "patient group"), and 40 healthy control group. Wechsler Intelligence Test(WAIS-RC)was used to assess the cognitive function of patients before and after treatment for 6 weeks. The side effects of 2, 4 and 6 weeks after treatment were observed by TESS. Results: Before treatment, there were significant differences in perception, arithmetic, number span, vocabulary, total number of digital symbols, correct number and mapping score among the three groups(P<0.05). After treatment, the scores in perception, arithmetic, vocabulary and number score of Shugan Jieyu group were higher than those before treatment, while the similarity score was higher than that before treatment. The results of the test were lower than those before treatment, and the difference was significant(t=-3.218, P=0.002; t=-2.314, P=0.038; t=-2.974, P=0.005; t=-3.151, P=0.037). After treatment, the scores of digital breadth test, vocabulary test and digital symbol test in sertraline group were better than those before treatment, with statistical significance(t=-3.241, P=0.013; t=-3.241, P=0.013; t=-3.112, P=0.001). Conclusions:(1)Shugan Jieyu Capsule is an effective and safe antidepressant.(2)The patients with depression have obvious cognitive impairment. After treatment with Shugan Jieyu Capsule and Sertraline Tablet, the cognitive function has been improved.

参考文献/References:

[1] 吕爽. 国内首发未治抑郁症患者认知功能P300特征的Meta分析[J].神经疾病与精神卫生,2014,5(14):477-481.
[2] 陈小平.抑郁症患者中医不同辨证分型脑内5-HT、NE、DA神经递质变化规律的研究[D].北京:北京中医药大学, 2014.
[3] 赵海京,马万千.抑郁症病程与中医证型相关性[J].2016, 29(4):62-63.
[4] 王亚军.舒肝解郁胶囊联合文拉法辛缓释片治疗抑郁症疗效观察[J].中国中医药咨讯,2011,3(18):194.
[5] NakanoY, Baba H, Maeshima H, et al. Executive dysfunction in medicated.remitted state of major depression[J]. JAffect Disord,2008,111(1): 46-51.
[6] Behnken A, Schoning S, Gerss J, et al.Persistent nonverbal me mory impairment in remitted major depression caused by encoding deficits[J]. J Affect Disord,2010,122(12):144-148.
[7] Henera-GuzmanI, Gudayol-FerreE, Herrera Abarea JE, et al. Major Depressive Disorder in recovery and neumpsychological functioning:effects of selective semtoninreuptakeinhibitor and dualinhibitot depression treatments on residual cognitive deficitsin patients with Major Depressive Disorder in recovery[J]. j Affect Disord,2010,123(13):341-350.
[8] 孙薇,吴博,石伟彬,等. 刺五加胶囊对抑郁大鼠海马组织TH、TPH表达的影响[J].现代生物医学进展, 2011, 11(22):4247-4249.
[9] 张犁.舒肝解郁胶囊治疗心血管神经症效果分析[J].中国社区医师(医学专Ik),2012,14(27):186.
[10] Roca M, Monzón S, Vives M, et al.Cognitive function after clinical remission inpatients with melan cholic and non-melan cholic depression:26 month follow-up study[J]. J Affect Disord, 2015,171:85-92.
[11] Koenig A M, Delozier I J, Zmuda M D, et al. Neuro psychological functioning in the acute and remitted States of late-life depression[J]. J Alzheimers Dis,2015,45(1):175-185.

相似文献/References:

[1]钟秋园.抑郁症患者焦虑评分及领悟社会支持评分的临床对照研究[J].赣南医学院学报,2015,(04):566.[doi:10.3969/j.issn.1001-5779.2015.04.022]
 ZHONG Qiu-yuan.Clinical Control Study on Anxiety and Perceived Social Support Scores in Patients with Depression[J].,2015,(12):566.[doi:10.3969/j.issn.1001-5779.2015.04.022]

备注/Memo

备注/Memo:
通信作者:王亚丽,女,硕士,副主任医师,研究方向:临床精神药理学。E-mail:shufort2012@sina.com
更新日期/Last Update: 2019-12-30